Proteomics and drug discovery in cancer

Matheus H Dias; Eduardo S Kitano; André Zelanis; Leo K Iwai

doi:10.1016/j.drudis.2015.10.004

Proteomics and drug discovery in cancer

Drug Discov Today. 2016 Feb;21(2):264-77. doi: 10.1016/j.drudis.2015.10.004. Epub 2015 Oct 17.

Authors

Matheus H Dias¹, Eduardo S Kitano¹, André Zelanis², Leo K Iwai³

Affiliations

¹ Laboratório Especial de Toxinologia Aplicada (LETA), Center of Toxins, Immune-Response and Cell Signaling (CeTICS), Instituto Butantan, São Paulo, Brazil.
² Laboratório de Proteômica Funcional, Instituto de Ciência e Tecnologia, Universidade Federal de São Paulo (ICT-UNIFESP), São José dos Campos, São Paulo, Brazil.
³ Laboratório Especial de Toxinologia Aplicada (LETA), Center of Toxins, Immune-Response and Cell Signaling (CeTICS), Instituto Butantan, São Paulo, Brazil. Electronic address: leo.iwai@butantan.gov.br.

PMID: 26484434
DOI: 10.1016/j.drudis.2015.10.004

Abstract

Proteomics has emerged as an invaluable tool in the quest to unravel the biochemical changes that give rise to the hallmarks of cancer. In this review, we present the advances and challenges facing proteomics technology as applied to cancer research, and address how the information gathered so far has helped to enhance understanding of the mechanisms underlying the disease and contributed to the discovery of biomarkers and new drug targets. We conclude by presenting a perspective on how proteomics could be applied in the future to determine prognostic biomarkers and direct strategies for effective cancer treatment.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Biomarkers, Tumor / metabolism
Drug Discovery*
Humans
Neoplasms / drug therapy
Neoplasms / metabolism*
Protein Interaction Mapping
Proteomics*

Substances

Biomarkers, Tumor